reference/14627251

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/14627251

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase II\|Journal Article\|Randomized Controlled Trial\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't\|Research Support, U.S. Gov't, P.H.S.
endingPage	5937
issn	0732-183X 1527-7755
issueIdentifier	25
pageRange	5929-5937
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	5929
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b52d36bbeb35469f69259f04186b2ff6 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_288d3b52e1434f2c41383491a215da02 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_9d564233b9543dd351385e715fd6a9da http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_4634c243785571d8327ee65dcc1b4370 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_e9081889dc95e89493a7ba161a76d7de http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5db0deb7d0a3d588be9cbfe27581edfc http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_3398dd9537fb87d0124f721d4dee76bf http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_b88662a17e22ebcca1707e323327d3e8
bibliographicCitation	Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA; North Central Cancer Treatment Group; Mayo Clinic; Eli Lilly & Company. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2005 Sep 01;23(25):5929–37. doi: 10.1200/jco.2005.13.953. PMID: 16135464.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a950a8385e2e884f50955222358e91b1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cb3f6336b0a251fe2deacd08164f9d26 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_117d3331ca9a439885e1bbc09e960fa0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b15879db4e30f5665bf452c9f62c44a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7425b7130d56f5edb3d00431791934b6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d6b2a21ab11147c07e1691719c7aa66a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_818bb00d9d5869c9e27ae95b86dfa153 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a45b97b19ba2c943cb84f3e8c9a01ab3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_213699703b169f302839a660b168efb0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_385e38e641cb18efbc3f562019c71d80 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d30ba41c7adf45f973ba574c93e966e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ffc07961b1d5226f7b19dbb2fbe7c867 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31ca83e65725086fc29559fd4eec3a90
date	2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/16135464 https://doi.org/10.1200/jco.2005.13.953
isPartOf	https://portal.issn.org/resource/ISSN/1527-7755 https://portal.issn.org/resource/ISSN/0732-183X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non–Small-Cell Lung Cancer
discusses	http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0005997
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D002289Q000188 http://id.nlm.nih.gov/mesh/D000971Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005971Q000008 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D006147Q000008 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D007262 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D006147Q000031 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D008175Q000473 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D002289Q000473 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D000068437
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837

Total number of triples: 81.